Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267391 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
A NA study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Endogenex.
- Recruiting
- Registry status
- NA
- Development phase
- 264
- Enrollment target
- 20
- Study locations
NCT06267391: Recruiting NA study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Endogenex.
NCT06267391 is a NA study of Diabetes Mellitus, Type 2 and Diabetes that is actively recruiting participants, run by Endogenex. The registered enrollment target is 264 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06267391, a NA study of Diabetes Mellitus, Type 2 and Diabetes, is actively recruiting participants, sponsored by Endogenex.
- RECRUITING
- Registry status
- NA
- Development phase
- 264 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Primary Outcome
Change in HbA1c (%) from baseline to Month 6
Conditions Studied
Interventions
- DEVICE ReCET Treatment
- DEVICE Sham Procedure
Study Locations (20)
Florida
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Mayo Clinic - Jacksonville
- Universal Axon Clinical Research LLC - Miami
- University of Miami - Miami
- Quantum Clinical Research - Miami Beach
- West Orange Endocrinology - Ocoee
- Advent Health - Orlando
- Orlando Health - Orlando
- Health Synergy Clinical Research - West Palm Beach
California
- Velocity Clinical Research, Gardena - Gardena
- Cedars-Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- Hoag Memorial Hospital Presbyterian - Digestive Health Institute - Newport Beach
- Velocity Clinical Research, Panorama City - Panorama City
Alabama
- University of Alabama - Birmingham
- Central Alabama Research - Birmingham
Iowa
- Heartland Medical Research, Inc. - Clive
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Illinois
- NorthShore University Health System - Evanston
Maryland
- John Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-10-01 |
| Phase | NA |
What NCT06267391 shows while recruiting
NCT06267391 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which ReCET Treatment is the first listed.
NCT06267391 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06267391 about?
NCT06267391 is a clinical study titled "Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes". This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
What is the current status of trial NCT06267391?
This trial is currently recruiting. It is a NA study. The enrollment target is 264 participants. The study started on 2024-05-01. Estimated completion is 2026-10-01.
What conditions does trial NCT06267391 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT06267391?
The interventions under investigation include: ReCET Treatment (DEVICE), Sham Procedure (DEVICE).
Who is sponsoring clinical trial NCT06267391?
This trial is sponsored by Endogenex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06267391 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06267391's enrollment target sits among peer trials
264 135th of 348 higher than 214 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI